Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
100 hedge funds and large institutions have $866M invested in Y-mAbs Therapeutics in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 45 increasing their positions, 22 reducing their positions, and 30 closing their positions.
105% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 22
8% more capital invested
Capital invested by funds: $804M → $866M (+$62.3M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.91% less ownership
Funds ownership: 60.91% → 60% (-0.91%)
15% less funds holding
Funds holding: 117 → 100 (-17)
57% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$45.8M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$18.5M |
| 3 |
BlackRock
New York
|
+$5.74M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$4.63M |
| 5 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
+$4.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$23.6M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$13.8M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$10.7M |
| 4 |
State Street
Boston,
Massachusetts
|
-$10.3M |
| 5 |
Millennium Management
New York
|
-$8.62M |
YMAB Hedge Fund Activity: Q2 2021 in Review
100 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q2 2021, worth a combined $866M — up 7.7% from $804M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of YMAB and 13 opened new positions — a net loss of 17 holders — while 22 trimmed existing stakes and 45 added.
The largest buyer was Wellington Management Group, adding an estimated $45.8M. The largest seller was Loomis, Sayles & Company, exiting entirely with an estimated $23.6M sold.
- 100 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q2 2021, down from 117 in Q1 2021.
- Funds reported $866M of Y-mAbs Therapeutics stock for Q2 2021, up 7.7% quarter-over-quarter.
- 13 funds opened new Y-mAbs Therapeutics positions in Q2 2021 and 30 closed out, a net change of -17 holders.
- The largest Y-mAbs Therapeutics buyer in Q2 2021 was Wellington Management Group, an estimated $45.8M added.
- The largest Y-mAbs Therapeutics seller in Q2 2021 was Loomis, Sayles & Company, an estimated $23.6M sold.
Based on aggregated 13F filings for Q2 2021.